This site is intended only for healthcare professionals resident in the United Kingdom
Nimenrix Dosing and Administration
Nimenrix (Meningococcal groups A, C, W135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neiserria meningitidis serogroups A, C, W135 and Y.*,†,1
Nimenrix dosing schedule:*,†,1
Route of administration1
- Immunisation should be carried out by intramuscular injection only
- The recommended injection site is the anterolateral aspect of the thigh in infants. The anterolateral aspect of the thigh or deltoid muscle is the recommended injection site for individuals from 1 year of age
*See prescribing information for further information
†Nimenrix should be used in accordance with official recommendations
Administration
Nimenrix™ is available as a single pack with two needles for reconstitution and administration (23G blue and 25G orange, 25mm).2 Nimenrix comes as a powder in a vial, with a solvent for solution for injection in a pre-filled syringe. These components require reconstitution prior to administration.1
Visuals adapted from visuals sourced from vecteezy.com.
How should Nimenrix be stored?1
Before reconstitution – Nimenrix should be stored in the refrigerator between 2°C and 8°C in its original packaging. It has a shelf life of 4 years, but the expiry date on the packaging should always be checked prior to use.
After reconstitution – Nimenrix should be used promptly following reconstitution. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If the vaccine is not used within 8 hours, it should not be administered.
References
1. Nimenrix. Summary of Product Characteristics, United Kingdom, Pfizer Ltd. Available here
2. Pfizer data on file, February 2020.
